文献速递多重用药老年慢病共病管理老年综合评估

多病共存老年人参与药物临床试验的态度:全国代表性调查

Attitudes on participation in clinical drug trials: A nationally representative survey of older adults with multimorbidity.
PubMed 文献 · J Am Geriatr Soc · 2024-03-14

该研究对1318名≥65岁且≥3种慢性病的美国老年人进行横断面调查,发现参与药物试验的主要障碍是担心副作用、服药过多和视频访视,而医生邀请最能促进参与,且更偏好面对面访视。

要点

  • 主要障碍:担心副作用48%、服药过多44%、安慰剂44%、视频访视33%。
  • 65%愿参加所有面对面试验,49%愿参加全视频试验;医生邀请影响最大(80%)。
  • 为现有问题(63%)比预防(44%)更愿考虑试验;获得更好医疗(79%)最重要。

核心结论

  • 多病共存老年人对药物试验的主要担忧是潜在副作用、服药过多和视频访视。
  • 医生对参与决策影响最大,且面对面访视更受偏好。
  • 为增加代表性不足老年人入组而提出的试验设计改变可能与患者报告偏好不一致。

研究设计与样本

  • 横断面互联网和电话调查,全国代表性样本为≥65岁且≥3种慢性病的成年人(NORC芝加哥大学Amerispeak面板),于2023年3月至4月进行。
  • 共调查1318人(互联网1142人,电话176人),平均年龄72.3±6.3(SD)岁,52%为女性。
  • 种族:83%白人,10%黑人或非裔美国人,5%西班牙裔或拉丁裔,1.1%亚裔;平均4.4±1.9种慢性病(共询问16种),服用7.5±3.3种药物。

主要发现

  • 障碍包括担心副作用(48%)、服药过多(44%)、安慰剂(44%)、行动不便(33%)、如厕需求(25%)、听力(19%)、视力(15%)。
  • 视频访视障碍为33%,在女性、黑人或非裔美国人受访者及≥80岁者中更高。
  • 65%愿参加所有面对面试验,49%愿参加全视频试验;旅行>1小时对66%的人困难,女性最难。
  • 25%黑人受访者存在信任担忧;照护责任或缺乏时间不是障碍。
  • 参与者最可能考虑针对其现有问题的药物试验(63%)而非预防(44%),若由医生(80%)或大学医疗系统(58%)邀请。

临床怎么用

  • 与多病共存老年人讨论药物试验时,应主动解释副作用风险、精简合并用药并说明安慰剂安排。
  • 医生邀请是促进参与的关键,应优先由医生发起试验讨论。
  • 优先提供面对面访视选项,并评估旅行>1小时、如厕、听力、视力等实际障碍。
  • 对女性、黑人或非裔美国人及≥80岁者,需特别关注视频访视可及性和信任问题。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Older adults with multimorbidity are under-represented in clinical drug trials. Their inclusion will not increase unless they are willing and able to participate. Data on motivators and barriers to participation in trials of new medications of older adults with multimorbidity are needed. METHODS: Cross-sectional internet and telephone survey of a nationally representative sample of adults ≥65 years with ≥3 chronic conditions (NORC University of Chicago Amerispeak Panel) conducted from March-April, 2023 to determine motivators and barriers to drug trial participation, described graphically and using statistics. RESULTS: Surveyed 1318 (1142 Internet, 176 phone) with mean age 72.3 ± 6.3 (SD), 52% women; race: 83% White, 10% Black or African American, 5% Hispanic or Latino, 1.1% Asian; 4.4 ± 1.9 chronic conditions (of 16 queried), taking 7.5 ± 3.3 medications. Barriers included fear of side effects (48%), taking too many medications (44%), placebo (44%), mobility (33%), bathroom needs (25%), hearing (19%), eyesight (15%), video visits (33%; higher in women, Black or African-American respondents, and those ≥80 years). Sixty-five percent would join all in-person trials, 49% would join all-video trials. Travel >1 h was difficult for 66%, most difficult for women. Trust was a concern in 25% of Black respondents. Caregiving responsibilities or lack of time were not obstacles. Participants were most likely to consider a drug trial for a problem they have (63%) versus prevention (44%) and if invited by a physician (80%) or University healthcare system (58%). Getting better care was ranked very important (79%) followed by helping others (57%). CONCLUSIONS: Major concerns of older patients with multimorbidity about participation in drug trials are potential side effects, taking too many medicines, and video visits. Physicians have the greatest influence on decisions and in-person visits are preferred. Proposed changes in trial design to increase enrollment of under-represented older adults may not align with patient-reported preferences.

来源:J Am Geriatr Soc,查看原文。版权归原作者所有。

引用

  1. Schwartz JB, Liu RY, Boscardin J, et al. Attitudes on participation in clinical drug trials: A nationally representative survey of older adults with multimorbidity. J Am Geriatr Soc. 2024. PMID: 38485469. doi:10.1111/jgs.18857

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。